生物医药企业必贝特开启申购 5个产品处于I期临床试验阶段

Core Viewpoint - Bibet (688759.SH) has initiated its subscription with an issue price of 17.78 yuan per share, focusing on innovative drug development for major diseases such as cancer and autoimmune disorders [1] Company Overview - Bibet is a biopharmaceutical company that emphasizes clinical value and is dedicated to the independent research and development of innovative drugs [1] - The company has one approved breakthrough therapy drug, BEBT-908, for the treatment of r/r DLBCL, and several other products in various stages of clinical trials [1][2] Product Pipeline - BEBT-908 is the first-in-class small molecule dual-target inhibitor designed for HDAC/PI3Kα, approved for multiple hematological malignancies and solid tumors [1] - BEBT-209 is in Phase III clinical trials, while BEBT-109 has been approved to start Phase III trials, and five other products are in Phase I clinical trials [1][3] - The company has multiple innovative drug candidates in preclinical research [1] Financial Performance - The company reported net losses of approximately 188 million yuan, 173 million yuan, and 55.998 million yuan for the years 2022, 2023, and 2024, respectively [4] - Bibet has not yet achieved profitability and anticipates significant ongoing R&D investments, which will likely prevent profit distribution or cash dividends in the short term [4] Assets and Equity - As of December 31, 2024, the total assets of the company are approximately 332.48 million yuan, with equity attributable to the parent company at around 290.22 million yuan [4] - The asset-liability ratio for the parent company is reported at 12.38% [4]